Pearl IRB and Trafalgar Ethics Board Partner to Deliver Integrated US-Canada IRB Review Services
Pearl IRB,LLC and Trafalgar Ethics Board, Inc. announce a partnership to provide one stop shop service for central IRB (Institutional Review Board) services for clients. The trend for research sponsors to conduct multi-center global clinical trials continues to grow, with the United States and Canada accounting for 60.5%1 of sponsored clinical trials in 2010. Pearl IRB, based in the United States in Indianapolis and Trafalgar Ethics Board headquartered in the Toronto area in Canada, join forces to deliver integrated United States–Canada study reviews.
“We have partnered to serve the needs of our clients in a more streamlined fashion,” shares Ali Thompson, Director of Trafalgar Ethics Board. “Both our Canadian clients and US based sponsors are demanding higher quality and increased efficiencies in the global regulatory oversight of their clinical trials. By working together to provide United States–Canada IRB reviews, we eliminate much duplication and help streamline work for our clients.”
Clinical trials are often delayed for many reasons including contract negotiations, budgeting issues, and IRB reviews. “We strive to decrease site review times by integrating our processes to provide parallel US and Canadian site reviews, states Diana Caldwell, President and CEO of Pearl IRB. “Additionally, we will partner to offer additional services that are of high value to our clients including medical writing, GCP/ICH assistance, and site training all of which reach across Canada and the US now.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
